牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ F-1/A [Amend] Registration statement for certain foreign private issuers Accession Number: 0001213900-20-003078 Act: 33 Size: 5 MB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] Registration statement for certain foreign private issuers Accession Number: 0001213900-20-002441 Act: 33 Size: 3 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-002343 Act: 34 Size: 27 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001393825-20-000028 Act: 34 Size: 59 KB 网页链接
$灿菲特生物制药(CANF)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001213900-20-001759 Act: 33 Size: 13 KB 网页链接
$灿菲特生物制药(CANF)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-20-001752 Act: 33 Size: 3 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-001160 Act: 34 Size: 29 KB 网页链接
$灿菲特生物制药(CANF)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001213900-20-000772 Act: 33 Size: 248 KB 网页链接
$灿菲特生物制药(CANF)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001213900-20-000778 Act: 33 Size: 249 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-000768 Act: 34 Size: 220 KB 网页链接